Prothena (PRTA) Chief Strategy Officer reports 66,942 shares and option grants
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Prothena Corp Public Ltd Co’s Chief Strategy Officer Anne Evans Kingston filed an initial ownership report showing her equity position in the company. She directly holds 66,942 Ordinary Shares and a series of employee stock options over additional Ordinary Shares.
The options cover 5,000 shares at $53.81 per share expiring on May 1, 2033, 3,000 shares at $30.30 per share expiring on February 27, 2034, and 14,080 shares at $14.95 per share expiring on March 5, 2035. Footnotes explain that each grant vests 25% on an initial date, then in equal monthly installments over four years, conditioned on her continued employment with Prothena on each vesting date.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Kingston Anne Evans
Role
Chief Strategy Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares, par value $0.01 per share | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 5,000 shares (Direct);
Ordinary Shares, par value $0.01 per share — 66,942 shares (Direct)
Footnotes (1)
- The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on May 1, 2024, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on February 27, 2025, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on March 5, 2026, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
Key Figures
Direct Ordinary Shares: 66,942 shares
Stock options at $53.81: 5,000 shares
Stock options at $30.30: 3,000 shares
+3 more
6 metrics
Direct Ordinary Shares
66,942 shares
Directly owned Ordinary Shares reported in Form 3
Stock options at $53.81
5,000 shares
Stock Option (Right to Buy), exercise price $53.81, expires May 1, 2033
Stock options at $30.30
3,000 shares
Stock Option (Right to Buy), exercise price $30.30, expires February 27, 2034
Stock options at $14.95
14,080 shares
Stock Option (Right to Buy), exercise price $14.95, expires March 5, 2035
Initial vesting schedule
25% at first vest date
Each option grant vests 25% on its initial vesting date
Ongoing vesting schedule
1/48th monthly
Remaining option shares vest in equal monthly installments over four years
Key Terms
Stock Option (Right to Buy), Ordinary Shares, vest and become exercisable, monthly installments, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" for multiple entries"
vest and become exercisable financial
"The shares subject to the option vested and became exercisable as to 25%..."
monthly installments financial
"vest and become exercisable with respect to 1/48th ... in successive, equal monthly installments"
Monthly installments are regular, fixed payments made each month to gradually pay off a larger amount, such as a loan or purchase. Think of it like paying for a big item in small, manageable parts instead of all at once. For investors, understanding installment payments helps gauge how debts are structured and how they might affect financial stability or cash flow over time.
continued employment financial
"subject to the Reporting Person's continued employment with the Issuer on each such vesting date"
Continued employment means that an individual remains in their current job without interruption. For investors, it signals stability and ongoing work that can affect company performance and future prospects. Like a steady heartbeat for a business, sustained employment helps ensure consistent operations and financial health.
FAQ
What does the Form 3 filing by Prothena (PRTA) executive Anne Evans Kingston show?
The Form 3 shows Anne Evans Kingston’s initial ownership in Prothena, including 66,942 Ordinary Shares and multiple stock option grants. These options give rights to buy additional shares at fixed prices over several years, subject to time-based vesting and continued employment conditions.
What stock options are reported for Anne Evans Kingston in Prothena (PRTA)?
She holds stock options over 5,000 Ordinary Shares at $53.81, 3,000 shares at $30.30, and 14,080 shares at $14.95. Each grant has its own expiration date and vests 25% initially, then monthly in equal installments over four years, contingent on continued employment.
How do the vesting terms work for Anne Evans Kingston’s Prothena (PRTA) options?
Each option grant vests 25% on a stated initial date, then vests 1/48th of the total monthly. Vesting continues on each monthly anniversary as long as she remains employed by Prothena, gradually increasing the portion of options that become exercisable over four years.
Does this Prothena (PRTA) Form 3 indicate stock purchases or sales by Anne Evans Kingston?
The Form 3 does not indicate purchases or sales; it reports existing holdings and option awards. All transactions are coded as holdings, meaning the filing establishes her baseline ownership position rather than recording new market trades in Prothena shares.